Overview
Lixisenatide (AVE0010) is a 44-amino-acid incretin peptides.">GLP-1 receptor agonist based on the exendin-4 sequence. Compared with exendin-4, it lacks a proline residue near the C-terminus and carries an added tail of six lysine residues, a modification intended to enhance stability. It was discovered by Zealand Pharma and developed by Sanofi.
Lixisenatide was approved by the European Medicines Agency in 2013 and by the US FDA in 2016 for type 2 diabetes, and it was also developed in a fixed-ratio combination with insulin glargine. Availability has since changed in some markets, with the standalone US product discontinued. Lixisenatide is classed as a short-acting agonist, and its profile is dominated by a strong, sustained slowing of gastric emptying, which makes it a useful tool for research focused on postprandial glucose regulation. Its cardiovascular outcome trial, ELIXA, was the first such study completed for the GLP-1 receptor agonist class. More recently, lixisenatide has attracted attention in Parkinson's disease research.
Mechanism studied
- Lixisenatide
- GLP-1 receptor
- Slowed gastric emptying
- Postprandial glucose
Lixisenatide binds the GLP-1 receptor with high affinity and activates Gs-cAMP signalling. In beta cells this potentiates glucose-dependent insulin secretion, while glucagon release from alpha cells is suppressed when glucose is elevated. Because its exposure fluctuates more than that of long-acting agonists, lixisenatide preserves a pronounced delay in gastric emptying; with continuous GLP-1 receptor stimulation this effect tends to undergo tachyphylaxis. Slower delivery of nutrients to the small intestine flattens postprandial glucose excursions, and this mechanism contributes substantially to its glycaemic profile in research settings. Lixisenatide also acts on central satiety pathways and has been shown to cross the blood-brain barrier in rodent studies.
Research highlights
- 01Discovered by Zealand Pharma and licensed to Sanofi; approved in Europe in 2013 and the United States in 2016.
- 02ELIXA, conducted in people with type 2 diabetes and a recent acute coronary syndrome, was the first completed cardiovascular outcome trial of a GLP-1 receptor agonist.
- 03Comparative research contrasts its gastric-emptying-driven postprandial effects with the fasting glucose emphasis of long-acting agonists.
- 04A phase 2 trial in early Parkinson's disease, published in 2024, reported findings that prompted calls for larger confirmatory studies.
- 05Open questions include how short- versus long-acting receptor exposure shapes tachyphylaxis of gastric effects.
Latest published research
738 papers on PubMed →Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis
Barbosa LM et al. · Heart rhythm · 2026 Oct 26 · PMID 42933519
Patient-Reported Outcomes Following Initiation or Simplification of Treatment With iGlarLixi in Adults With Type 2 Diabetes: A Narrative Review
Giorgino F et al. · Diabetes, obesity & metabolism · 2026 Oct 19 · PMID 42897097
Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data
Wang X et al. · European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026 Oct 13 · PMID 42867646
Development and validation of qualitative methods for the detection of GLP-1 receptor agonists in serum and dried blood spots by LC-HRMS/MS for doping control purposes
Borschel L et al. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026 Oct 8 · PMID 42874322
GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study
Brahmbhatt S et al. · HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026 Oct 7 · PMID 42856761
Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study
Nielsen VW et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 Oct 3 · PMID 42828450
Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues
Popa Ilie IR et al. · BMJ open · 2026 Oct 1 · PMID 42823110
Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study
Zhang S et al. · Diabetes, obesity & metabolism · 2026 Oct · PMID 42473266
Live feed from PubMed (NCBI) for “Lixisenatide”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.
Registered studies
76 on ClinicalTrials.gov →- Not yet recruiting
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
NCT07881783 · Novartis Pharmaceuticals · 2026-10-30
- Active not recruiting
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
NCT05220917 · Brigham and Women's Hospital · 2021-08-01
- CompletedPhase 4
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
NCT06716424 · Sanofi · 2025-01-06
- RecruitingPhase 4
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235 · Shanghai Zhongshan Hospital · 2025-12-13
- RecruitingPhase 4
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
NCT06671587 · Sanofi · 2024-12-10
- Not yet recruitingPhase 4
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
NCT07173712 · Yanbing Li · 2026-03-15
- CompletedPhase 2
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
NCT03439943 · University Hospital, Toulouse · 2018-06-13
- CompletedPhase 3
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
NCT05413369 · Sanofi · 2022-07-07
From the public ClinicalTrials.gov registry for “Lixisenatide”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.
Key references
- [1]Manufacturer's prescribing information — FDA / EMA / ANVISA
- [2]Pfeffer et al., 2015 — N Engl J Med 373:2247–2257
FAQ
Lixisenatide has a relatively brief half-life compared with Fc-fused or albumin-binding agonists. Its receptor exposure therefore rises and falls, which preserves a strong effect on gastric emptying and makes it particularly relevant to postprandial glucose research.
ELIXA was a placebo-controlled cardiovascular outcome trial in adults with type 2 diabetes who had experienced a recent acute coronary syndrome. It met its non-inferiority objective for cardiovascular safety and was the first completed outcome trial for a GLP-1 receptor agonist.
Both are derived from exendin-4. Lixisenatide modifies the C-terminal region by removing a proline and adding six lysines. These changes alter pharmacokinetics and receptor binding compared with exenatide while retaining resistance to DPP-4 degradation.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.